Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06095440 · ClinicalTrials.gov registry record
A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center
A clinical trial of Hepatorenal Syndrome, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06095440: Recruiting study of Hepatorenal Syndrome, sponsored by Methodist Health System.
NCT06095440 is a study of Hepatorenal Syndrome that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 500 participants, above the 324-participant average among 5 other Hepatorenal Syndrome trials with a reported enrollment target (54% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06095440, a study of Hepatorenal Syndrome, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \[1\].
Primary Outcome
Mortality rates, morbidities, complications, and other clinically relevant outcomes in HRS-AKI patients
Conditions Studied
Interventions
- OTHER Hepatorenal Syndrome outcome in Patients at Methodist Health systems
Study Locations (1)
Texas
- Liver Institute of Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-05-13 |
| Est. Completion | 2025-05-13 |
What NCT06095440 shows while recruiting
NCT06095440 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 324-participant average among 5 other Hepatorenal Syndrome trials with a reported enrollment target (54% higher).
The record links to 1 condition, with Hepatorenal Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Hepatorenal Syndrome outcome in Patients at Methodist Health systems is the first listed.
NCT06095440 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06095440 about?
NCT06095440 is a clinical study titled "A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center". Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes...
What is the current status of trial NCT06095440?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-05-13. Estimated completion is 2025-05-13.
What conditions does trial NCT06095440 study?
This clinical trial studies the following conditions: Hepatorenal Syndrome.
What interventions are being tested in trial NCT06095440?
The interventions under investigation include: Hepatorenal Syndrome outcome in Patients at Methodist Health systems (OTHER).
Who is sponsoring clinical trial NCT06095440?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06095440 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatorenal Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg
COMPLETED · Early Phase 1
-
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
COMPLETED · Phase 2
-
Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
COMPLETED · Phase 3
-
International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI